These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20048432)

  • 21. [Treatment of elderly hypertension with Ca channel blockers].
    Saito F; Kushiro T
    Clin Calcium; 2005 Oct; 15(10):1717-25. PubMed ID: 16199919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atheroprotective properties of nifedipine.
    Yamagishi S; Takeuchi M
    Int J Tissue React; 2005; 27(2):63-7. PubMed ID: 16035650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine.
    Mason RP; Marche P; Hintze TH
    Arterioscler Thromb Vasc Biol; 2003 Dec; 23(12):2155-63. PubMed ID: 14512371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and EBM].
    Toba A; Kuwajima I
    Clin Calcium; 2010 Jan; 20(1):9-15. PubMed ID: 20048428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained-release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use.
    Silvestry FE; St John Sutton MG
    Eur Heart J; 1998 Aug; 19 Suppl I():I8-14. PubMed ID: 9743438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Calcium antagonists: current and future applications based on new evidence. Renal protective action of calcium channel blockers].
    Kimura G
    Clin Calcium; 2010 Jan; 20(1):94-9. PubMed ID: 20048440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis.
    Survase S; Ivey ME; Nigro J; Osman N; Little PJ
    Vasc Health Risk Manag; 2005; 1(3):199-208. PubMed ID: 17319105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antioxidants in hypertension and cardiovascular disease.
    Schiffrin EL
    Mol Interv; 2010 Dec; 10(6):354-62. PubMed ID: 21263161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine.
    Toba H; Nakagawa Y; Miki S; Shimizu T; Yoshimura A; Inoue R; Asayama J; Kobara M; Nakata T
    Hypertens Res; 2005 Aug; 28(8):689-700. PubMed ID: 16392774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fundamentals of calcium channel blockers.
    Das G
    Int J Clin Pharmacol Ther Toxicol; 1988 Dec; 26(12):575-84. PubMed ID: 3061939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Differential therapy with calcium antagonists].
    Scholze JE
    Herz; 2003 Dec; 28(8):754-63. PubMed ID: 14689111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis.
    Allanore Y; Borderie D; Périanin A; Lemaréchal H; Ekindjian OG; Kahan A
    Arthritis Res Ther; 2005; 7(1):R93-100. PubMed ID: 15642147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of calcium channel blockers in the treatment of cardiovascular diseases.
    Herman ZS
    Pol J Pharmacol; 1999; 51(2):201-6. PubMed ID: 10425650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis.
    Godfraind T
    Philos Trans R Soc Lond B Biol Sci; 2005 Dec; 360(1464):2259-72. PubMed ID: 16321796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium channel blockers in treatment of hypertension.
    Muntwyler J; Follath F
    Prog Cardiovasc Dis; 2001; 44(3):207-16. PubMed ID: 11727278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Calcium channel blockers (calcium antagonists). Background, effects and use].
    Mikkelsen EO
    Ugeskr Laeger; 1995 Jun; 157(26):3750-4. PubMed ID: 7631450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions.
    Yoshii T; Iwai M; Li Z; Chen R; Ide A; Fukunaga S; Oshita A; Mogi M; Higaki J; Horiuchi M
    Hypertens Res; 2006 Jun; 29(6):457-66. PubMed ID: 16940709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects.
    Hasegawa H; Takano H; Kohro T; Ueda K; Niitsuma Y; Aburatani H; Komuro I
    Hypertens Res; 2006 Sep; 29(9):719-29. PubMed ID: 17249528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcium entry blockers and their effects on glucose metabolism.
    Kingma PJ; Simons JP; Nieuwenhuijzen Kruseman AC; Wolffenbuttel BH
    Neth J Med; 1990 Feb; 36(1-2):32-8. PubMed ID: 2179750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pleiotropic effects of new generation calcium channel blockers on cardiovascular protections].
    Ogimoto A; Higaki J
    Clin Calcium; 2013 Apr; 23(4):569-74. PubMed ID: 23545747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.